
Recursion Pharmaceuticals Inc
NASDAQ:RXRX

Intrinsic Value
The intrinsic value of one
RXRX
stock under the Base Case scenario is
4.11
USD.
Compared to the current market price of 4.18 USD,
Recursion Pharmaceuticals Inc
is
Overvalued by 2%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Recursion Pharmaceuticals Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Recursion Pharmaceuticals Inc
Balance Sheet Decomposition
Recursion Pharmaceuticals Inc
Current Assets | 584.1m |
Cash & Short-Term Investments | 500.5m |
Receivables | 46.1m |
Other Current Assets | 37.6m |
Non-Current Assets | 721.1m |
PP&E | 204.8m |
Intangibles | 493.9m |
Other Non-Current Assets | 22.4m |
Free Cash Flow Analysis
Recursion Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Recursion Pharmaceuticals Inc
Revenue
|
59.8m
USD
|
Cost of Revenue
|
-55.9m
USD
|
Gross Profit
|
3.9m
USD
|
Operating Expenses
|
-577.9m
USD
|
Operating Income
|
-574m
USD
|
Other Expenses
|
-742k
USD
|
Net Income
|
-574.8m
USD
|
RXRX Profitability Score
Profitability Due Diligence
Recursion Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Score
Recursion Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
RXRX Solvency Score
Solvency Due Diligence
Recursion Pharmaceuticals Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Score
Recursion Pharmaceuticals Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RXRX Price Targets Summary
Recursion Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
RXRX
is 7.99 USD
with a low forecast of 5.05 USD and a high forecast of 10.5 USD.
Dividends
Current shareholder yield for RXRX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
RXRX
stock under the Base Case scenario is
4.11
USD.
Compared to the current market price of 4.18 USD,
Recursion Pharmaceuticals Inc
is
Overvalued by 2%.